- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06299982
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
March 1, 2024 updated by: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
750
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qinghong Zhou
- Phone Number: +86 18911301578
- Email: zhouqinghong@3sbio.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years old, both male and female.
- Diagnosis of plaque psoriasis according to the Chinese Guideline for the Diagnosis and Treatment of Psoriasis (2018).
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) .
- Other inflammatory diseases.
- Active autoimmune diseases.
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 608 160 mg W0+80 mg Q2W
Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection for 12 weeks.
|
608 160 mg at week 0 + 80 mg Q2W (5 cycles)
|
Experimental: 608 160 mg Q4W
Participants will receive 160 milligrams 608 once every four weeks (Q4W) by subcutaneous injection for 12 weeks.
|
608 160 mg Q4W (3 cycles)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Time Frame: At Week 12
|
At Week 12
|
Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
Time Frame: At Week 12
|
At Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
Time Frame: At Week 12
|
At Week 12
|
Percentage of Participants Achieving a ≥100% Improvement in Psoriasis Area and Severity Index (PASI 100)
Time Frame: At Week 12
|
At Week 12
|
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0)
Time Frame: At Week 12
|
At Week 12
|
Adverse events (AE)
Time Frame: 20 weeks
|
20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 15, 2024
Primary Completion (Estimated)
January 30, 2025
Study Completion (Estimated)
March 20, 2025
Study Registration Dates
First Submitted
February 28, 2024
First Submitted That Met QC Criteria
March 1, 2024
First Posted (Actual)
March 8, 2024
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSGJ-608-PsO-III-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis Patients
-
PfizerCompleted
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
Clinical Trials on 608 Q2W
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Recruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompletedDiabetes Mellitus, Type 2China
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...RecruitingPulmonary Disease, Chronic ObstructiveChina
-
Sumitomo Pharma America, Inc.CompletedHealthy | ADMEUnited States
-
Haisco Pharmaceutical Group Co., Ltd.Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Eli Lilly and CompanyTerminatedRheumatoid ArthritisUnited States, Germany, Taiwan, France, Japan, Mexico, Poland, Russian Federation, Spain, Colombia, Argentina, Greece, New Zealand, South Africa, Australia, Korea, Republic of, Brazil, Italy, Malaysia
-
Suzhou Transcenta Therapeutics Co., Ltd.Completed